Charles Schwab Investment Management Inc. Has $12.61 Million Holdings in Xencor, Inc. (NASDAQ:XNCR)

Charles Schwab Investment Management Inc. increased its stake in Xencor, Inc. (NASDAQ:XNCR) by 7.0% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 626,988 shares of the biopharmaceutical company’s stock after acquiring an additional 40,788 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.90% of Xencor worth $12,609,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in Xencor in the second quarter valued at approximately $154,000. Diversified Trust Co boosted its position in shares of Xencor by 7.8% during the second quarter. Diversified Trust Co now owns 14,076 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 1,017 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in Xencor by 3.0% during the 2nd quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the biopharmaceutical company’s stock valued at $587,000 after acquiring an additional 900 shares in the last quarter. Baillie Gifford & Co. boosted its holdings in Xencor by 3.3% during the 2nd quarter. Baillie Gifford & Co. now owns 23,530 shares of the biopharmaceutical company’s stock worth $445,000 after acquiring an additional 744 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of Xencor by 3.3% in the second quarter. Bank of New York Mellon Corp now owns 500,708 shares of the biopharmaceutical company’s stock valued at $9,478,000 after acquiring an additional 15,974 shares in the last quarter.

Xencor Trading Up 0.1 %

Shares of XNCR opened at $25.34 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. Xencor, Inc. has a 1-year low of $15.31 and a 1-year high of $27.24. The company has a market capitalization of $1.77 billion, a P/E ratio of -7.92 and a beta of 0.69. The firm’s 50 day simple moving average is $22.51 and its 200 day simple moving average is $20.60.

Xencor (NASDAQ:XNCR) last announced its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. Xencor’s revenue for the quarter was down 81.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.40) EPS. Sell-side analysts forecast that Xencor, Inc. will post -3.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on XNCR. Royal Bank of Canada boosted their price target on shares of Xencor from $31.00 to $34.00 and gave the stock an “outperform” rating in a report on Thursday, September 26th. Wedbush reaffirmed an “outperform” rating and set a $38.00 price target on shares of Xencor in a research report on Thursday, November 7th. JPMorgan Chase & Co. upped their price target on shares of Xencor from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, BMO Capital Markets reaffirmed an “outperform” rating and set a $34.00 target price (up previously from $32.00) on shares of Xencor in a report on Friday, November 8th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $36.50.

Insider Buying and Selling at Xencor

In other news, VP John R. Desjarlais sold 68,684 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company’s stock, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Bassil I. Dahiyat sold 3,366 shares of the stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $24.02, for a total transaction of $80,851.32. Following the sale, the chief executive officer now directly owns 352,615 shares of the company’s stock, valued at $8,469,812.30. The trade was a 0.95 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 136,050 shares of company stock worth $3,277,609 over the last three months. Company insiders own 5.23% of the company’s stock.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.